Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -29.60% | +0.00% | +0.00% | +987.25% | +10461.32% |
| Gross Profit Growth | -29.60% | +0.00% | +0.00% | +2459.86% | +10461.32% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +16.23% | +8.17% | +11.95% | +11.24% | +12.18% |
| Weighted Average Shares Diluted Growth | +16.23% | +9.08% | +11.95% | +11.24% | +12.70% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +8654.84% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +61.86% | +64.74% | +56.22% | +21.54% | +58.25% |
| Book Value per Share Growth | -71.79% | +30.57% | +41.15% | +125.93% | +863.55% |
| Debt Growth | +122.31% | +85.20% | +57.07% | -57.00% | -64.13% |
| R&D Expense Growth | +17.61% | +31.63% | +6.52% | +28.61% | +29.34% |
| SG&A Expenses Growth | +13.83% | +13.19% | +33.42% | +44.17% | +74.32% |